ロード中...
HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant
BACKGROUND: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab bindin...
保存先:
| 出版年: | Gynecol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4380649/ https://ncbi.nlm.nih.gov/pubmed/25602714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.01.533 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|